News about Clinical Trials

Thryv Therapeutics Advances THRV-1268 Programme with Phase II/III Trial and FDA Fast Track Status

Thryv Therapeutics initiates Phase II/III clinical testing and secures FDA Fast Track status for THRV-1268, advancing a potential first-in-class therapy for Long QT Syndrome.

Clinical Trials | 27/04/2026 | By News Bureau |  183

Ascletis Pharma Completes US Phase 2 Enrollment for ASC30 GLP-1R Agonist

Ascletis Pharma completes US Phase 2 enrollment for ASC30, an oral GLP-1R agonist for diabetes. The 13-week study evaluates safety, efficacy, and tolerability in 100 patients, with topline results expected in Q3 2026.

Clinical Trials | 27/04/2026 | By News Bureau |  147

ModeX Therapeutics Doses First Patients in Trial of Novel Tetraspecific Therapy for B-Cell Lymphoma

ModeX Therapeutics initiates clinical testing of MDX2003, a next-generation multispecific antibody therapy designed to enhance immune response and improve outcomes in B-cell lymphoma patients.

Clinical Trials | 24/04/2026 | By News Bureau |  153

Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer

Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.

Clinical Trials | 23/04/2026 | By News Bureau |  215

Roche Reports Strong Phase III Results for Fenebrutinib in Multiple Sclerosis

Roche’s investigational drug fenebrutinib shows significant reduction in relapse rates and disease activity in multiple sclerosis, offering potential for improved long-term outcomes in patients.

Clinical Trials | 23/04/2026 | By News Bureau |  180

AskBio's Viralgen to Supply Commercial Drug for Parkinson's Phase 2 Trial

AskBio’s Viralgen will supply commercial-scale drug product for the REGENERATE-PD Phase II trial of ametefgene parvec (AB-1005), leveraging next-generation manufacturing to deliver high-purity gene therapy for Parkinson’s disease.

Clinical Trials | 22/04/2026 | By News Bureau |  137

AstraZeneca's Tozorakimab Hits Key Phase 3 Goal in COPD Trial

AstraZeneca reports positive Phase III MIRANDA trial results for tozorakimab in COPD, marking its third successful pivotal study and reinforcing the potential of its IL-33-targeting biologic to transform respiratory care.

Clinical Trials | 21/04/2026 | By News Bureau |  152

NHS Speeds Up Clinical Trials, Accelerating Patient Access to New Treatments

The Government-backed reforms and Euro 137 million investment cut trial set-up times, strengthening the UK’s position as a global leader in clinical research and innovation.

Clinical Trials | 17/04/2026 | By News Bureau |  136

GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021

Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.

Clinical Trials | 16/04/2026 | By News Bureau |  333

Samsung Bioepis Starts Phase 1 Trial for Nectin-4 ADC SBE303

Samsung Bioepis launches Phase 1 trial of SBE303, a Nectin-4 targeting ADC, marking a key step in advancing its oncology pipeline and Antibody-Drug Conjugate development.

Clinical Trials | 16/04/2026 | By News Bureau |  113